Davis Polk advised the representatives of the several underwriters in connection with the SEC-registered offering of 6,500,000 shares of common stock of Applied Genetic Technologies Corporation. The common stock is listed on the Nasdaq Global Market under the symbol “AGTC.”

Applied Genetic Technologies Corporation is a clinical-stage biotechnology company that uses a proprietary gene therapy platform to develop transformational genetic therapies for patients suffering from rare and debilitating diseases.

The Davis Polk corporate team included partner Yasin Keshvargar and associates David Li and Stephen H. Karp. The intellectual property and technology team included counsel Bonnie Chen and associate Daniel P. Kearney. Partner Patrick E. Sigmon provided tax advice. All members of the Davis Polk team are based in the New York office.

Copy link to share post